目的：采用Meta分析系统性评价Rho激酶抑制剂Ripasudil对青光眼的治疗效果。

方法：通过检索三个数据库(Pubmed、Web of Knowledge和CNKI)，检索Ripasudil治疗青光眼的临床试验，检索发表日期为2015-01/2019-04。采用眼内压(IOP)作为结局指标，WMD和95% CI评价结果，并根据青光眼类型分为原发性开角型青光眼、继发性青光眼、多种类型进行亚组分析。

结果：共纳入9篇文献，全部为英文文献，与对照组相比，试验组IOP显著降低(WMD=-2.96，95% CI -3.48～-2.45，P<0.001)。去除导致高度异质性的文献后，亚组分析组间差异明显。

结论：Ripasudil对降低眼压有显著作用，可用于治疗青光眼，但对不同类型的青光眼治疗效果仍有差异。Ripasudil有结膜充血等副作用，但停药以后副作用消失。

METHODS:According to the Cochrane systematic review method, we searched three databases(Pubmed, Web of Knowledge and CNKI). The change of intraocular pressure was used to assess the effect of ripasudil, WMD with 95% confidence intervals(CI)were used to report the outcome. Subgroup analysis was performed according to different types of glaucoma.

RESULTS:A total of 9 trials all in English, totally 3446 patients, Meta-analysis showed that compared with before-treated groups, after-treated groups have significant lower IOP(Test of WMD= -2.96 95% CI: -3.48 to -2.45, P<0.001), which indicates that ripasudil has great efficacy of curing glaucoma.

CONCLUSION:Ripasudil have significant efficacy in reducing IOP, which can be used as a treatment for glaucoma.